ABEO
NASDAQ · Biotechnology
Abeona Therapeutics Inc
$7.46
+0.06 (+0.81%)
Financial Highlights (FY 2026)
Revenue
4.29M
Net Income
52.50M
Gross Margin
73.7%
Profit Margin
1,223.1%
Rev Growth
+60.4%
D/E Ratio
0.13
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 73.7% | 73.7% | 45.4% | 45.4% |
| Operating Margin | 1,081.1% | 973.0% | -8.6% | -10.0% |
| Profit Margin | 1,223.1% | 1,161.9% | -11.2% | -11.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 4.29M | 2.68M | 39.71M | 32.89M |
| Gross Profit | 3.16M | 1.97M | 18.02M | 14.92M |
| Operating Income | 46.41M | 26.04M | -3,427,237 | -3,280,542 |
| Net Income | 52.50M | 29.46M | -4,431,314 | -3,676,832 |
| Gross Margin | 73.7% | 73.7% | 45.4% | 45.4% |
| Operating Margin | 1,081.1% | 973.0% | -8.6% | -10.0% |
| Profit Margin | 1,223.1% | 1,161.9% | -11.2% | -11.2% |
| Rev Growth | +60.4% | +60.4% | +12.5% | +7.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 20.33M | 20.33M | 47.63M | 42.47M |
| Total Equity | 161.62M | 161.62M | 217.43M | 201.44M |
| D/E Ratio | 0.13 | 0.13 | 0.22 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 48.29M | 28.60M | -4,969,444 | -4,544,257 |
| Free Cash Flow | — | — | -4,447,710 | -3,857,678 |